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The use of prescription medication in prisons in Northern Ireland  
Introduction 
Substance use is common among those incarcerated in prisons across Europe and globally, with levels 
of use disproportionately high compared with the general population (Boys et al 2002; EMCDDA, 2018; 
2012). Drugs have for many decades been illegally used and legally prescribed within prisons, profits 
have been generated from selling drugs, and substance use has remained high on the public health 
agenda within prisons (Kolind and Duke 2016). More prisoners are using a wide range of substances 
and prison life is, as a consequence, often characterised by drug-related issues (Boys et al 2002, 
EMCDDA, 2018; Kolind and Duke 2016). Research has consistently evidenced the high risk nature of 
the prison environment for drug initiation/relapse/ unsafe forms of drug taking behaviour, 
transmission of HIV and other blood-borne infection (ECMDDA 2012; Strang et al. 2006). Drug using 
prisoners have generally experienced multiple deprivation, low educational achievement, 
unemployment and many have experienced periods of homelessness (DoH, 2018a; EMCDDA 2012).  
Poor physical and mental health are also common, including dual diagnosis of substance use related 
disorders, with significant psychiatric conditions including post-traumatic stress disorders (PTSD), 
anxiety, depression and psychosis. Risk of suicide remains high among prisoners who use substances 
(ECMDDA, 2012; WHO, 2007).  
Substance use must also be understood through the lens of the everyday social life within prison: the 
prisoner culture, social networks and economics (see Wheatley, 2007). Drug use and the market 
systems within prisons can place further emphasis on existing inequalities in these environments for 
example, between powerful and more vulnerable prisoners. Substances of all types in the prison 
system are a profitable commodity (both economically and or in terms of symbolic capital). Therefore, 
they have potential to exert a powerful influence on the everyday prison environment (Kolind and 
Duke, 2016). 
Rationale for the study 
The use of prescription medication has been highlighted as a particular area of concern within prisons 
in Northern Ireland (CJINI, 2016). This assertion is in tune with concerns about the high levels of use 
within the wider community in Northern Ireland, as evidenced in regional statistical data (DoH, 2018a).   
The research team recently completed work throughout the prison estates in Northern Ireland as part 
of a large study funded by the National Institute of Health Research (Higgins et al. 2018), examining 
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the use of new psychoactive substances (NPS). Interviews with prisoners and Personal and Public 
Involvement (PPI) and work with prison staff highlighted the need to focus further on prescription 
medication as a key issue and a contemporary challenge of working in the prison environment. The 
team were funded by the Health and Social Care Public Health Agency to conduct a scoping study 
within the prison estate to further examine the role played by prescription medication within that 
context. 
Aims and objectives 
The primary aim of the current research was to examine the use of prescription medication in prisons 
across Northern Ireland from the perspectives of prisoners, prison officers and healthcare staff. We 
did not seek to examine the prescribing of these substances, rather the use of drugs that are 
commonly prescribed and consumption of these drugs with and/or without prescription. It also aimed 
to examine how prescription drug use fits into the wider portfolio of drug use in prisons.  
Principal research questions: 
 Are prescription drugs (PDs) more or less available than illicit drugs and/or NPS? 
 Are they used singularly or in tandem with other drugs?  
 Is use always based on availability?  
 What might help in terms of diversion?  
However, while the study did not set out to examine the prescribing of substances, the issue of 
prescribing practices emerged frequently during discussions with all participants and because of this, 
represented an integral part of the analysis and subsequent findings. 
 
Report structure 
The report is divided into five sections. Section One provides details on the study design, research 
methods and analytical approach. The study uses a qualitative method, drawing on the voices and 
experiences of prisoners, prison officers and healthcare staff to examine the issue from a broad 
perspective. Section Two sets out the background to the study, briefly charting the changing pattern 
of drug use, the rise in the misuse of PDs and situates the research in a Northern Ireland context, 
where the study took place.  Reporting of results are presented across two sections: Section Three 
examines patterns of use as reported by participants, revealing broad agreement on current trends. 
It also looks at availability of PDs in prison, summarising what participants perceived to be the main 
drivers of increased availability. Section Four looks at the issue of risk management from the 
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perspective of prisoners, prison staff and healthcare staff. The concept of ‘risk’ was used here to get 
a better understanding of motivation; the things that prompt people to make certain decisions and 
the basis upon which decisions are made. Section Five concludes with a summary and discussion of 
the main points, including recommendations for consideration.  
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SECTION ONE - RESEARCH DESIGN  
Methodology 
The study design encompassed the use of focus group interviews with prisoners, with prison staff and 
with healthcare staff. Focus groups are commonly used to gather opinions about a defined topic. 
Participants are purposively selected because they have certain things in common that relate to the 
topic of interest (Krueger and Casey, 2009). They are designed to encourage open discussion and 
sharing of views in a relaxed environment. Focus groups are not used to gather personal information 
of a sensitive nature. 
Initially, it was proposed that we would conduct one-to-one interviews with healthcare staff, as 
opposed to focus groups, because of the limited number of healthcare staff in each prison. However, 
it was difficult to set-up appointment dates and times that suited individual healthcare staff, within 
the time schedule of the study. Therefore, rather than miss an opportunity to speak with willing 
participants, we adopted a pragmatic approach and agreed on one date and time that suited 
everyone. 
Focus group interviews with prisoners were conducted prior to focus groups with prison staff and 
healthcare staff. Data collected from prisoners informed the basis of broad key areas that were 
investigated and corroborated/or not through subsequent data collection with staff. 
As a result of heavy work demands, the number of prison staff and healthcare staff that eventually 
participated in the focus group in prison B was small (three and two respectively). However, the 
diversity of the constituencies across the three different groups ensures that the sample remains rich 
in terms of representativeness, allowing us to explore the influence of different factors (Lewis, 2003: 
85).   
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Sample  
The sample included prisoners and staff with varying roles working within the prison (see Table One 
for participant characteristics).  
Table 1: Focus group participant characteristics 
FOCUS GROUP PRISON A PRISON B 
Prisoners Nine people participated. The group 
met regularly to lead their own 
discussion group on issues related 
to substance use and general 
wellbeing. All participants were 
either present or past users of the 
AD:EPT service. 
Seven people participated. Their ages 
ranged from approximately 21 years to 
mid-50’s. All participants were either 
present or past users of the AD:EPT 
service. 
Prison staff Seven people participated in the 
group discussion. The majority 
included Prison Officers. A small  
number of ancillary staff attended. 
Three participants took part. This 
included Prison Officers with various 
levels of seniority.  
Healthcare staff Five people participated. The group 
included G.P., Clinical Director,  
Mental health nurse, Nurse 
Manager and Psychologist. 
Two people took part. Both participants 
had responsibility for primary care 
prescribing. 
  Sample total = 33 
Research ethics 
The study was submitted for ethical approval to Business Services Organisation, Office for Research 
Ethics Committees Northern Ireland (ORECNI) on 12th March 2017. Ethical approval was confirmed on 
8th June 2017.  
The primary ethical issues in this study centre round recruitment, informed consent, data collection 
and storage and the possibility of unintended harms. 
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Recruitment 
We were aided in recruitment of prisoner participants by the local drug and alcohol support service – 
Alcohol & Drugs: Empowering People through Therapy (AD:EPT)1, which operates throughout all 
locations. They also assisted in access arrangements for carrying out the focus groups. AD:EPT staff 
asked individuals engaged with the service if they were willing to take part in a focus group to discuss 
their perceptions of prescription drug use in prison. 
  
Whilst conducting other ongoing work, the team had also availed of the opportunity to discuss this 
prescription drug use study with prison staff and healthcare workers. They all valued the opportunity 
to have the issue researched and they agreed principle in advance (Governor, senior officers and 
officers and healthcare staff for participation in the focus groups). In order to minimise burden to 
prison staff and upon the advice of senior officers, focus groups were held after the weekly prison 
meeting for senior officers and staff. Discussions with healthcare staff took place at a time and location 
which was convenient for the majority of participants. 
 
Informed consent 
Informed consent was sought at the beginning of each focus group.  Participant information sheets 
were passed to those interested in taking part in the study (via the AD:EPT team) one week prior to 
data collection. Participants were asked to read this prior to completing the interview. In the event 
that participants are unable to read, a member from the AD:EPT team read the information to the 
participant. Prior to the commencement of the focus group, participants were asked to sign and date 
a consent form to indicate that they understood all the information given.  
Participants were free to withdraw from the study at any point and were made fully aware of this at 
all stages throughout the research. The process of informed consent was a continuous one and until 
the point of data analysis, participants were able to withdraw from the study. Participants were 
informed of this right in the information sheet and reminded prior to participating in the focus group 
at consent stage. 
 
 
                                                          
1 1 AD:EPT is a service organised by Start360, providing a range of services to people in custody who have 
problems with drug and alcohol use. See http://www.start360.org/ 
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Data collection and storage 
In accordance with Standard Operating Procedure for Management of Data, participants were 
provided with detailed information sheets informing them of the purpose of the study, risks and 
benefits, and the ways in which data will be used.  
All data was held securely on password protected computers within QUB to protect against 
unauthorised access. All personal identifiers were removed from transcripts prior to analysis to ensure 
that participants cannot be identified. 
Confidentiality and Disclosure  
The nature of drug related research will elicit the divulgence of information on behaviour that is 
deemed criminal.  Prior to participation respondents were assured that researchers will, to the best 
of their ability, keep all information confidential. Participants were not asked to discuss personal 
experience and were encouraged not to share specific and identifiable details of criminal behaviour 
inside or outside the prison. If participants had disclosed information leading us to believe that they 
or someone else is at risk of harm, we had planned to follow Supporting Prisoners at Risk (SPAR) 
protocol and inform AD:EPT staff and relevant prison staff.  No such disclosures arose over the course 
of data collection. 
Participants were advised of all disclosure protocols in the participation information sheet and again 
prior to commencement of the focus group interview.Prison staff were also made aware of conditional 
confidentiality and informed that the team will endeavour to keep all data confidential unless they 
divulge information that leads us to believe that they or anyone else is at risk of harm. 
Wellbeing of participants 
Due to the sensitive nature of the research, there was a risk of distress on behalf of participants. In 
the event that an individual becomes distressed during the interview, we had developed protocols 
which involved the Principal Investigator (PI) being informed, with that information then being passed 
onto the AD:EPT team and other relevant persons if required. The team has extensive experience in 
conducting research with vulnerable populations and in the area of substance use. Again, nothing 
arose requiring such action over the course of fieldwork 
Researcher Safety 
The research team attended civilian training for working in the prison estate and had experience of 
conducting research in this setting through ongoing work. Focus groups took place in the Prisoner 
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Development Unit of the prison with a prison officer located outside of the room. Two researchers 
were present at each focus group. 
Incentivisation 
Prisoners participating in the focus group were compensated for their time with £5 phone call credit, 
in line with remuneration for our ongoing work in the prisons. 
Data analysis 
Interview data were transcribed verbatim and anonymised through the removal of potential 
identifiers. Transcripts were uploaded to NVivo for thematic analysis by two members of the research 
team. Cross-checking of themes took place within the wider team. Data coding was accomplished in 
two stages. The first step initial coding involved the generation of numerous category codes without 
limiting the number of codes.  At this stage, the team listed emerging ideas, drew relationship 
diagrams and identified keywords used by respondents frequently as indicators of important themes. 
The second stage involved more focused coding where the team eliminated, combined or subdivides 
the coding categories identified in the first step. Attention was focused on recurring ideas and wider 
higher order themes connecting the codes across respondent groups.  
Analytic framework 
The concept of ‘risk’ and how that risk is managed, is used here to frame our analysis. Recently, the 
way people confront and negotiate risk in their everyday lives, the way risk is perceived and how this 
affects individual behaviour has become an important area of public policy (Zinn, 2015). Policy makers 
have become attracted to the potential of behavioural economics to improve the effectiveness of 
government and improve lives. 
The meaning of risk as applied here, is to provide both an explanation for how risk is determined 
among the different populations within the challenges of the prison environment, and as a framework 
for understanding reactions to these different perceptions of risk. For example, how is probability of 
risk weighed up against consequences? To what extent are people aware of the consequences of risk-
taking? What are the motivations for risk-taking? What decisions are made based on perceptions of 
risk? Are there tensions between different participants on how best to manage risk?  These are some 
of the issues drawn from the data. 
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Limitations of the study 
The nature of this research is sensitive and draws a sample of participants from a vulnerable 
population. It was anticipated that all three operational prison establishments in Northern Ireland 
would participate in the study. However, despite receiving ethical approval, we were unable to secure 
the agreement of one of the three prisons, which means that the study does not reflect the views of 
female prisoners.  
A further possible study limitation derives from how the sample was obtained. As prisoner participants 
were recruited via AD:EPT, these participants will have experience of being a service user. However, 
securing the co-operation of AD:EPT was central to engaging interested individuals and for securing 
practical arrangements for discussions to take place. Furthermore, diversity was encompassed within 
the prisoner sample because, while all participants were involved with AD:EPT in some capacity, their 
engagement was both current and past, allowing possibly differences in perspective to be acquired. 
The prisoner sample also varied by age, providing an opportunity to capture any age related 
perceptions.   
All participants essentially self-selected to take part, therefore it is possible that the findings represent 
particular views or situations. However, the study was predicated on voluntary participation. In 
addition, focus group constituents represent the diversity of the prison environment and all had 
specific experiences which were highly relevant to the study topic, allowing a more detailed 
exploration of the phenomena of interest - primarily the identification of preferences, consumption 
patterns and motivation of prescription drug use in prisons – than would hitherto be obtainable via a 
quantitative survey. 
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SECTION TWO – BACKGROUND 
Changing patterns of drug use  
Patterns of drug use are changing globally, with a growing trend for synthetic alternatives to 
traditional illicit drugs. Contemporary data reflects an increasingly graduated and fractured drug scene 
(EMCDDA 2012, 2017, 2018; UNOCD, 2015). The former dichotomy between a relatively small number 
of highly problematic drug users and a more significant number of recreational and experimental users 
is changing to a more complex and dynamic picture. The widening array of psychoactive substances, 
increased accessibility and a much greater sophistication in technical knowledge surrounding drug 
use, has meant that the use of multiple substances has become more prevalent. Polydrug use2 can 
also be used to describe the tendency to use different substances in different settings or contexts, or 
simply reflect regular multi-substance use related to drug dependence. Compared to traditional illicit 
drugs, NPS are inexpensive, relatively easy to source and frequently more potent. 
Overall, the substance types that are used together depends not only on personal preferences, but 
also on other factors such as availability locally, specific scenes/fashion, and in the case of prescribed 
psychoactive medicines (such as benzodiazepines for example), on local prescribing practices. More 
extensive use of PDs is likewise contributing to the changing patterns in drug use (UNOCD, 2017).  
Concern about the harms to individuals and society associated with the increased availability and use 
of NPS has resulted in legislative changes to control production and supply. For example, in the UK, 
the Psychoactive Substances Act, implemented in 2016, restricts the availability of NPS, making the 
production, supply or intent to supply a criminal offence. The Act focuses on penalising suppliers 
rather than consumers. Those found in possession of NPS for personal use are not criminalised unless 
possession is in a ‘custodial institution’ (for example, an adult prison, young offenders centre, short-
term holding facility)3.  
As noted by Ralph et al (2017), the exclusion of those in ‘custodial institutions’ from prosecution 
reflects the increased concerns at the extent and use of drugs in prison, such as those documented in 
recent HM Inspector reports (e.g. HMIP 2014; 2015; 2016).  For example, a review of changing patterns 
of substance misuse in adult prisons in England and Wales (HMIP, 2015) reported a move away from 
the use of opiates and Class A drugs towards the misuse of PDs. The review also identified the growing 
use of NPS as a major problem.  
                                                          
2 Polydrug use is broadly defined as ‘the use of more than one drug’ (EMCDDA, 2002). 
3 http://www.legislation.gov.uk/ukpga/2016/2/pdfs/ukpga_20160002_en.pdf (page 4) 
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Prescription drug use in prison 
As was the case with NPS, certain groups are considered more vulnerable in terms of likelihood of use 
and dependency, including young people who have come through the care system, the homeless 
population, those with mental health issues and those incarcerated. In relation to the use of NPS by 
those in prison, a report by EMCDDA (2018) notes that:  
The rationale for choosing specific substances in prison is likely often to be explained by 
pragmatic considerations, such as availability and price, rather than the personal preferences 
of the user. (Ibid: 7) 
Moreover, more vulnerable populations are inclined to veer towards the cheapest and most potent 
substances (Novak et al. 2016). 
The prison environment is one that is particularly ripe for illicit use of PDs for a number of reasons. 
Firstly, capacity to access PDs in prison far outweighs that of illicit drugs. Due to the very nature of the 
fact the drugs are prescribed, sniffer dogs trained to detect the scent of illicit substances cannot pick 
up the scent of these substances, in cases where they are smuggled into the prison. Secondly, there is 
potential for diversion in prison whereby PDs can be considered something of a currency; individuals 
often trade the drugs they are prescribed. There are reports that this sometimes occurs under duress 
on when more vulnerable prisoners are involved. Thirdly, the threat of sanction is perceived lower 
among prisoners in terms of use of PDs in comparison with illicit substances; cannabis and cocaine for 
example, remain detectable in urine for longer periods than some PDs (Wolf, 2017). The risks 
associated with use of PDs are similar to that of illicit substances and vary by drug type. The EMCDDA 
estimate that one quarter of all drug related hospital admissions were directly associated with PDs, 
primarily benzodiazepines and opiates (EMCDDA, 2017)  
In response to rising concerns around non-medical use of PDs in prisons, the Royal College of General 
Practitioners has published guidance for clinicians on safer prescribing practices within the prison 
environment (RCGP, 2011). The guidance includes a traffic light system through which clinicians are 
discouraged from prescribing ‘red medicines’ in prisons, to carefully consider prescribing ‘amber 
medicines’ and to prescribe ‘green medicines’ as first choice. Some ‘red medicines’ such as 
benzodiazepines and fentanyl were considered to have ‘significant diversion potential’ (2011: 14).  
In line with this, the Northern Ireland Health and Social Care Board (HSCB) published advice in 2015 
specifically regarding the prescribing of pregabalin and gabapentin. The general guidance highlighted 
the risks of misuse and advised practitioners to prescribe pregabalin and gabapentin appropriately to 
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minimise the risks of misuse and dependence (HSCB, 2015). The guidance stated that ‘the misuse of 
gabapentin and pregabalin has been noted for some years in clients attending substance misuse 
treatment and recovery services, and within secure environment settings.’  (2015: 3).  
In the past, patterns of substance misuse in prisons have never directly reflected those found in the 
community (HMIP, 2015). Rather there appeared to be evidence of a preference for using depressants 
such as heroin and cannabis, to assist prisoners to ‘kill time’, over stimulants such as cocaine, crack 
cocaine and ecstasy, which many associate with a ‘club’ or party scene in the community. Over recent 
years a growing evidence base has emerged of changing patterns of substance misuse in prisons, such 
as the move towards prescribed medications and NPS, and away from Class A drugs and cannabis 
(HMIP, 2015). 
Drug use in the general population 
Information on drug use among the general population in the UK can be derived from representative 
surveys4. For example, the Crime Survey for England and Wales (2016/17) indicates that 34.2% of 
adults aged 15 to 59 reported they had used an illicit substance at some point in their life, 8.5% 
had used drugs the previous year (Home Office, 2017). According to the Scottish Crime and Justice 
Survey (2014/15) 29.5% of adults aged 16-59 in Scotland had tried drugs at least once in their 
lifetime, 8.5% reported using drugs in the previous year. According to the All-Ireland Drug 
Prevalence Survey (2014/15) Northern Ireland had lower prevalence rates of illicit drug taking 
than other regions in the UK with 27.7% of adults aged 15-64 reporting they had used illicit drugs 
at least once in their lifetime and 5.9% saying they had used drugs in the previous year (DoH, 
2015).  
It is more difficult to estimate the number of problem drug-users using general survey data. For 
example, those outside of these age ranges and people who do not live in private households (for 
example people in prisons, nursing homes or the homeless) will be excluded from the survey. 
However, UK regional drug misuse databases can provide an indication of recent drug use by problem 
users, although problem use is defined slightly differently by each region, making regional 
comparisons difficult. In England, the adult substance misuse statistics from the National Drug 
                                                          
4 Differences in the way the data is collected across the individual surveys means they are not directly 
comparable. However, they are useful for indicating regional patterns.   
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Treatment Monitoring System (NDTMS) reported the largest proportion of people presenting for 
treatment was for opiate (mainly heroin) dependence (53%) (PHE, 2018).   
Statistics from the most recent Northern Ireland Substance Misuse Database 2016/17 show that 
among those presenting to services with problem drug and/or alcohol misuse, cannabis was the most 
commonly used drug, indicated by nearly two-thirds (65.8%) of people presenting to services. Over a 
third of people reported using cocaine (36.9%) and benzodiazepines (35.1%). Across Northern Ireland, 
one in five people using drugs indicated that they took at least one prescription drug (20.3%) (DoH, 
2018a).  
Drug related deaths 
The most recent drug related death statistics for Northern Ireland (NISRA, 2019) show that while drug-
related deaths account for less than 1% of total deaths registered in Northern Ireland each year, there 
has been a 60% increase in the number of deaths from drug-related causes over the past decade (from 
2007 to 2017). Forty per cent of all drug-related deaths in 2017 involved diazepam, compared with 
24% in 2007. The number of reported deaths attributed to pregabalin/gabapentin rose from zero in 
2007 to 33 in 2017, while the number of deaths attributed to tramadol tripled in the same period, 
reflecting the growing prevalence of use within Northern Ireland. Consistent with the general 
literature, people living in areas of high deprivation were four times more likely to die of drug-related 
causes than those in the least deprived areas (NISRA, 2019).  
When compared to data on drug related deaths in the UK, a different pattern of use is evident, with 
higher proportions of deaths in Northern Ireland attributed to opiates/opioid analgesics (60.8%) 
compared with 26.8% for the UK as a whole (Corkery et al. 2013). As found in previous years, 
hypnotics/sedatives; other opiates/opioid analgesics; antidepressants; alcohol in combination; and 
anti-psychotics play a proportionately greater role in Northern Ireland than in other parts of the UK. 
Meanwhile, Northern Ireland had a substantially lower proportion of deaths attributed to 
heroin/morphine and methadone than Britain. Some of these regional differences has, in part, been 
attributed to differences in prescribing practices across the UK (ibid: 85).  
Prescription Medication  
Illicit use of PDs, also referred to as non-medical prescription drug use (NMPDU) and dependency 
associated with said substances have escalated across Europe (EMCDDA, 2018; 2012). NMPDU is 
defined as self-treatment of a medical condition with unauthorised prescribed drugs, as well as being 
used to ‘achieve euphoric states’ (Novak et al., 2016). The European Monitoring Centre for Drugs and 
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Drug Addiction (EMCDDA) refers to the phenomenon as ‘misuse of medicines’ and defines it as ‘the 
use of a psychoactive medicine for self-medication, recreational or enhancement purposes, with or 
without a medical prescription and outside accepted medical guidelines.’  The groups of drugs 
commonly misused include sedatives and hypnotics (e.g. benzodiazepines, barbiturates and z-
hypnotics); opioids and opioid substitution treatment drugs; and stimulants, particularly those used 
to treat attention deficit and hyperactivity disorder (ADHD). These substances can be obtained 
through regular prescribing practices, diversion of medicines and online vendors, particularly the ‘Dark 
Web’ (RAND, 2017). The United Kingdom is one of a number of European countries with the highest 
reported levels of NMPDU/ misuse of medicines (EMCDDA, 2017).  
Wherein once NPS filled a niche within the traditional drug market, prevalence estimates indicate that 
PDs now hold this position (EMCDDA, 2017). Growing concern about the problems caused by some 
prescribed medicines was a key factor in the commissioning of a public health evidence review by 
Public Health England (PHE) to examine available data and literature on dependence and withdrawal 
symptoms associated with prescribed medicines, and how they can be prevented and treated. 
Included within the scope of the review are benzodiazepines, Z-drugs, GABA-ergic medicines, opioid 
pain medications, antidepressants and community prescribing (prescribing in hospitals and prisons 
has been excluded from the review). The review is due to report in spring 2019. 
The Northern Ireland context 
There has long been an undercurrent of prescription drug misuse in Northern Ireland with reported 
high prescribing rates, particularly of sedatives in the treatment of anxiety and depression. When 
comparing prescribing trends, Northern Ireland has significantly higher levels of anti-depressant 
prescribing than the rest of the UK (Kelly et al. 2003), including significantly higher anti-depressant 
prescribing costs per capita than other UK regions (Donnelly, 2014).  
Much of this has been attributed to the legacy of the Troubles (Bunting et al. 2013; O’Reilly and 
Stevenson, 2003; Tomlinson, 2007); poor physical health in the population generally (Newtown et al. 
2015) and high levels of socio-economic disadvantage and deprivation (Abel et al. 2016).  
Recent estimates of the prevalence of anti-depressant prescribing in Northern Ireland from 2011 to 
2015 by Shevlin et al. (2019), indicates that anti-depressant prescribing remains higher in Northern 
Ireland than in the rest of the UK. The authors used administrative data linkage techniques to carry 
out a full population-based assessment of anti-depressant prescribing. They reported that the 
percentage of the Northern Ireland population aged 16 or over receiving a prescription for anti-
depressant medication was 12.3% in 2011 and 14.3% in 2015, and over the five-year period was 24.3% 
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(ibid, 3). While the authors noted several limitations of the research (e.g. not all anti-depressants were 
included in the analysis), they found that prescribing rates were likely to be higher than the prevalence 
of depressive disorders. The study noted the likelihood that factors other than depression (such as 
socio-economic disadvantage) is associated with anti-depressant prescribing, suggesting that 
‘alternative non-pharmacological forms of help and support for people with problems associated with 
low mood are needed.’ (2019: 6).  
Recent health inequalities data for Northern Ireland (DoH, 2018b) is consistent with existing literature 
reporting a significant association with socio-economic disadvantage and increased mental ill-health.  
For example, the rate of suicide and self-harm in the most deprived areas in Northern Ireland is 
approximately three and a half times the rates in the least deprived areas. While prescription rates for 
mood and anxiety increased across all areas, the rate in the most deprived areas was two-thirds higher 
than in the least deprived in 2016 (ibid: 23). In addition, the area of alcohol and drugs was among the 
largest inequality gaps recorded for the majority of Trusts (alongside self-harm, smoking in pregnancy 
and teenage births).  
The inequality gap in drugs related mortality was the most notable deprivation-related widening of 
gaps, with rates in the most deprived Local Government District (LGD) areas between two and three 
times the LGD average rates (ibid: 6).  
There is an extensive literature on the ways in which poverty is said to impact on mental health, 
although the relationship is complex, both in terms of how mental health is measured and assessing 
the direction of causality (Payne, 2012). For example, poor mental health can impact on an individual’s 
employment opportunities, leading to poverty. At the same time, poverty may lead to mental health 
difficulties as a result of stress and low self-esteem that come from trying to manage on low income 
(Daly and Kelly, 2015).  However, associations have been found between poverty and increased stress 
and anxiety, hospital admissions, out-patient use, suicide and parasuicide (e.g. Weich and Lewis, 1998; 
Butterworth et al. 2009; Weich et al. 2006; Stafford et al (2008) – all cited in Payne et al. 2011). 
Similarly, research has reported that social problems, including mental ill health, drug abuse, 
imprisonment, social mobility, are worse in unequal rich countries (Wilkinson and Pickett, 2009; 2018). 
The international literature reports that while the relationship between conflict and poverty is 
complex, poverty and high levels of inequality are nevertheless high risk factors for conflict 
(Bloomberg and Hess, 2002; Goodhand, 2003). Evidence shows how areas that experienced the 
highest intensity of violence during the Troubles were areas with more households on extremely low 
incomes (Fay et al. 1999), while the number of death and injuries resulting from the Northern Ireland 
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conflict has been greatest in the most disadvantages areas (Hillyard et al. 2005). Likewise, significantly 
higher rates of deprivation, together with poor physical and mental health were reported for those 
with ‘high’ experience of Troubled related conflict compared to those with little or no experience 
(Tomlinson, 2016; 2013).  
Health professionals have also become more aware of the mental health needs of individuals and 
families impacted by transgenerational trauma (where trauma is transferred from one generation to 
the next) again, as a legacy of the Troubles (Commission for Victims and Survivors, 2015).  
Alongside these factors, an evaluation of mental health services in Northern Ireland (Wilson, et al. 
2015) reported a lack of alternative therapeutic services in the community and provided evidence that 
a medical model approach still dominated mental health care in certain areas in Northern Ireland.  
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SECTION THREE -  FINDINGS  
PATTERN OF USE 
It is not possible to know exactly the extent and type of drug misuse in prisons or in the wider 
community (MHIP, 2015) and this study did not seek to establish prevalence of substance use. Rather 
the specific use of PDs in prison was investigated via discussions with prisoners, prison staff and 
healthcare staff. Areas of enquiry included the identification of preferences, consumption patterns, 
motivation and so forth. From the perspective of participants, a number of key themes emerged which 
inform our understanding of this issue. 
There was widespread agreement among prisoners, prison staff and healthcare staff that the use of 
PDs has increased substantially over the past three to four years, resulting in a situation where PDs 
now surpassed illicit drugs in terms of supply and demand.   Discussions revealed definable trends in 
usage of PDs – both in relation to prevalence and in the combination of consumption patterns.  A 
number of drugs were frequently referred to by all participants as being the most common in use. 
These were: 
Codeine (opioid pain medication) 
Diazepam (benzodiazepine) 
Fentanyl (opioid pain medication) 
Lyrica (a brand name for Pregabalinan anti-convulsant/pain medication) 
Methadone (a synthetic opioid substitute) 
Tramadol (opioid pain medication) 
Subutex (a brand name for buprenorphine, an opiate substitute) 
Xanax (benzodiazepine) 
It was also noted that certain drugs will wax and wane in terms of their commonality/popularity, 
although views on the status of specific drugs sometimes differed between prisoners and prison staff. 
For example, prisoners were more likely to describe Diazepam as ‘out of the picture now’ (Participant, 
Prison B), or to have been taken over by another drug, as described by a participant in Prison A: 
Diazepam was a big thing but then subutex came in. 
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Meanwhile, prison staff were more likely to consider diazepam to still be an issue, citing it as among 
the drugs found when carrying out ‘search and report’ procedures.  
However, currently the consensus across research sites points to pregabalin as being ‘probably 
number one’, holding constant for the past three to four years.  Opioid pain medication (e.g. codeine 
and tramadol) was reported by healthcare staff to have also remained reasonably constant over the 
same period. Xanax was described by healthcare staff in Prison A as increasing in use within the past 
year and, from their experience, trending both in the community and within the prison site.  
Meanwhile, there were much less references made to NPS, with prison staff suggesting that currently 
these substances were not so much of an issue because PDs were more readily available and also of 
good quality. When querying this further, part of the reason was thought to be due to the 
unpredictable nature of NPS. Comparisons were drawn with jails in England, where NPS is highly 
prevalent, and where the prisons are bigger with much larger populations. The speculation was that 
in smaller jails like those in Northern Ireland, there will be ‘two or three prisoners that will be the top 
dogs in those houses so obviously they want to control it’ (Prison staff, Prison B). Hence, 
unpredictability makes NPS harder to control. 
The presumption of some prison staff was that a shift towards NPS may come about if supply of PDs 
deteriorated. This was how one Officer in Prison A described the situation: 
If they stop the medication without anything then that’s going to push them towards the 
illicit drugs going down the road of spice – it hasn’t hit as big in here and I asked the 
prisoners why, and they said nobody likes it. But if there’s nothing, that’s the alternative - 
right we can’t get pregabalin – we’ll go to spice. 
In terms of consumption patterns, healthcare staff reported regularly treating prisoners who have had 
problems as a result of taking prescription medicines in combination with other drugs (both illicit and 
prescription medication diverted from other sources) and/or taking PDs well above the recommended 
dosage. Healthcare workers reported a changing landscape, where before the main issue they would 
be faced with was treating opiate dependence, now it was more likely to be polydrug use, as it sits 
within the drug use trajectories – and which is considered more difficult to manage. As one healthcare 
worker (Prison A) noted ‘there is no quick fix for that’.   
Offenders in both Prisons described similar incidents that they were aware of, where a combination 
of drugs were taken as a matter of course, and where exceeding the dosage was not uncommon. At 
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the same time, prisoners wanted to make it clear that not all prisoners abuse PDs. They felt aggrieved 
because they believed they were being unfairly judged based on the behaviour of others.  
What was evident, was an awareness by prisoners of the composition of particular prescription 
medication and the potential outcomes. In Prison B for example, fentanyl and xanax in particular were 
highlighted as being extremely risky compared to other PDs, mostly because of the strength of the 
substance and the difficulty in relation to dosage management. This was how two different 
participants described these PDs: 
Fentanyl mixed with anything actually – you’re playing with fire because it’s so strong – 
fentanyl is that strong that Naloxone won’t reverse it, it’s a dangerous thing with anything. 
(Prisoner, Prison B) 
Xanax is a slow release substance – when people take it they think they’re taking sub or a 
line of something they’re used to and they put out a big line…It’s the most underestimated 
drug I’ve ever taken, no exaggeration. (Prisoner, Prison B) 
 
In relation to pattern of use, an associated and significant sub-theme is that the pattern of usage of 
prescription medication within the prison estate is a reflection of general trends within the 
community, albeit in nuanced ways. This was the opinion of the following clinician (Prison A) who drew 
similarities in prescription drug use between patients in his local practice (located in an area of high 
deprivation) and his patients in prison: 
Well what I would say is, prison is a reflection of society… I’m a GP outside and work here as 
well and we see a lot of prescription drug uses in society you know, so every prison is going to 
be a very concentrated reflection of the patients…which are from areas of deprivation…places 
where actually resources are fewer and there is more over-prescribing.  So we get that very 
tightly through our doors through the 4000 people that come through here. So yes, I definitely 
think prescription use is a major problem. 
The majority of prison staff expressed similar opinions, describing the issue of PDs as something that 
co-exists in the community, with those coming into prison already on a range of legitimately 
prescribed medication, with the expectation that their existing medication will be maintained. Or, they 
are already taking PDs, illicitly obtained or diverted from other sources, with the expectation that they 
will be able to source similar drugs while in prison. 
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Views from prisoners also point to the use of prescription medication being an issue which coexists 
with life in the wider community. The following participant (Prison A), situated the use of PDs within 
the context of violence related activity as a consequence of ‘the Troubles’ legacy in Northern Ireland: 
There is one thing I will say about most of the ones in this room - they have either been shot or 
beat by paramilitaries and the troubles legacy is still running through the likes of diazepam, 
the likes of tramadol… all of us in here we’ve all been done [by the paramilitaries].  That’s 
where you see a pattern that it is tramadol, pregabalin, gabapentin, codeine.  They are being 
prescribed because of what has happened and then from there on in your tolerance goes 
through the roof and maybe you are taking two KPac one week and then about six months 
down the line you could be taking eight of them a day and it just keeps going up and up and 
up.   
Conversations with all participants supported the view expressed by prison staff that large numbers 
of prisoners come into prison with medication which has been prescribed by their G.P. Common 
conditions that the medication is prescribed to treat include mental health problems such as 
depression, anxiety, stress and pain relief from debilitating medical conditions. 
It was the view of both prison staff and healthcare staff that the wide availability of PDs within the 
community per se is one of a number of drivers behind the increased use of PDs in prison. This was a 
consistently recurrent theme throughout the interviews. There were common viewpoints attributing 
this to the recent conflict, with implications of an intergenerational affect – where PDs has become 
commonplace: 
For years it was blamed on the Troubles and the fallout from the troubles. We’re getting a 
generation now that have been on medication since they were kids, pre-teens, whether that’s 
to do with the troubles, their mother and fathers medication, I don’t know but as he says, they 
don’t care. (Prison officer, Prison A) 
Just as increased mental health issues have been documented in the community, one issue running 
constant throughout discussions with all participants was the prevalence of poor mental health among 
prisoners. 
The following healthcare participant (Prison A) was adamant that the problem of the misuse of PDs 
cannot be looked at in isolation, as only being applicable in the prison environment. The participant 
not only firmly situated the issue in the community, but also viewed it as a consequence of inadequate 
23 
 
 
community services. In particular, a lack of services to deal with childhood trauma was believed to 
escalate the problem: 
Well I think when you have more community services, I think prison is not the problem I think 
the problem is what is available in the community for a lot of these young people, our issues 
are things like childhood trauma experiences so somebody who is 8 has an ACE [adverse 
childhood experience] or whatever you call it…Then they get to 11 and don’t know how to deal 
with it and their mate is there saying ‘oh I took this tablet it helps me to calm down’, they take 
a Diazepam and all of a sudden they are on this journey. So it’s trying to pick up those traumatic 
experiences as a kid to try and manage that more effectively. 
Links with the community were reiterated among other healthcare staff, with the belief that trends in 
the community impacted on trends in prison:  
It’s to do with the trends at the minute and the trend in the community would be legal 
medication so our trends seem to be the same, whether its xanax or pregabalin, stuff like that 
are big hitters in the community. (Healthcare staff, Prison A) 
However, while legitimately prescribed medication may increase availability in the community in 
general, it is only one part of the bigger picture.  
There were a number of factors which repeatedly featured in discussions with all participants about 
what is driving increased availability of (and demand for) PDs in prison.  Mostly these centred on things 
like cost, profit, evasion, suppression and quality, all of which is reflective of the general literature (e.g. 
CJINI, 2016; CSJ, 2015; EMCDDA, 2012; HMIP, 2015). While participants focused their discussion on 
availability in prison, conversations were often interspersed with references to the community, which 
made it difficult at times to separate the two locations. This is also an indication of how much the issue 
is interconnected with the rise in prescription drug use in wider society. These views are summarised 
below: 
Cost:  
All participants noted that PDs are considerably cheaper than traditional ‘illicit’ drugs. The situation 
was described as basic economics - the emergence of the ‘dark web’ and the ease of access to internet 
sources has both increased supply and dampened down prices.  
it’s easy to get it off the internet because you know what you are looking for so boys will tell 
me they will order 500 Diazepam from China and it just comes in a huge big box - or not even 
a huge big box. (Healthcare staff, Prison A) 
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They’re cheaper than other drugs outside. (Prisoner, Prison B) 
It’s the availability of PDs on the outside too – seven years ago people were bringing in 
shitloads of coke – now they’re bringing in 40 foot lorries full of blues cos they’re getting it so 
cheap – the dark web. (Prisoner, Prison B) 
Profit margins/Supplementary income:  
Because PDs are cheaper (and easier) to obtain than illicit drugs in the community, there are more 
financial incentives to bringing them into prison where demand is greater, meaning their value is 
considerably higher, meaning profit margins are bigger.  Profits may not only be restricted to 
increasing prisoner income but may, on occasions, be used to supplement family income.  
I suppose it is a self-dependant industry so it is, so you do have family members come in and 
smuggle them in on visits as well because it is actually funding a family in the community, 
which is sad but it’s reality. (Healthcare staff, Prison A) 
Lucrative business – people can charge a lot of money in here for something that can be bought 
so cheap outside. 100% mark-up. (Prisoner, Prison B) 
Concealment: 
Prescribed medication is considered easier to hide, particularly the likes of Diazepam (e.g. internally 
secreted) and medications which come in clear patches which were perceived to be easily hidden (e.g. 
in the mouth). 
I’ve a lot of boys that are taking patches. So the patches are clear, so they are coming in 
through visits, the guys are keeping them in their mouth. I see boys every day of the week who 
have fentanyl and morphine patches in their mouth and they are not going to find them. 
(Healthcare staff, Prison B) 
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Evasion:  
It is less problematic to get PDs into prison because sniffer dogs are only trained to detect mostly 
illegal substances. They are not trained to detect prescribed medication because of the important 
medicinal role they play in treating illnesses and the fact that they are widely used legitimately within 
the community.  
They’re undetectable to our drug dogs, we can’t train our drug dogs to detect prescription 
meds because staff would fail, visitors who have chronic illnesses would fail, if you look at the 
percentage of our population who are on prescription medication – we would have very quiet 
visits and that is the scenario we are in and that’s the undetectable currency that they are 
dealing in. (Prison staff, Prison A) 
Also connected to evasion was the opinion that there was less chance of PDs being detected in a 
regular drug test because they leave the body quicker than most illicit drugs.  
Cannabis stays in the body for 28 days and they were getting caught, so Cannabis went away 
for a long time. Yellows and Blues were coming in about the time we got rid of Cannabis…they 
moved onto different things, find different things that you could get in past the dogs and would 
get out of your system sooner. (Prison staff, Prison B) 
Lyrica don’t show up on the drug tests unless they do a full screen and you only get a full screen 
if you are bringing drugs in or under suspicion. People don’t want to give up their TV…takes 
four months to get it back. (Prisoner, Prison A) 
Quality assurance: 
The issue of ‘quality assurance’ emerged more often in discussions with prisoners than other 
participants in relation to what was driving supply and demand and, as a consequence, wider 
availability. Quality in this context can be described as the perceived superiority of PDs in terms of 
their composition -  part of the reasoning being that because PDs are made in a controlled medical 
setting, their component was purer, so the risk of purchasing something substandard was reduced. 
This is how one participant described his thoughts on the issue: 
You know fentynal is manufactured in a laboratory, it’s the cleanest hit of gear that you are 
ever going to get, cleaner than any heroin that you are ever going to get. That’s 100 
micrograms for whatever…you know exactly what that is going to do.  You could get a bag of 
gear and it could be crap.  If you get this patch you know exactly what it is and you’ll say ‘right 
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ill pay this, whatever it is for it’ cause you know you are going to get the hit.  It’s good, it’s 
clean, it’s made in a lab. (Prisoner, Prison A) 
According to healthcare workers in both prison sites, there was also a perceived safety element to it, 
where PDs were viewed as ‘less risky’ because they were something that can be prescribed by the 
medical profession. The irony, as pointed out by healthcare workers and prison staff alike, is that there 
is no guarantee that PDs obtained from other sources (e.g. the internet, unlicensed suppliers) are what 
they claim to be. In fact, in all probability the risks may be greater, given the lure of financial 
profiteering to be made from counterfeit medicines. Similarly, when people choose to self-medicate 
the risks of certain combinations of PDs can be detrimental and/or fatal.   
As noted above, it was clear that prisoners were attuned to the risks involved. Although some 
prisoners may be more risk aware than others, leading to a situation of bullying or the subtle 
harassment of those with less awareness. For example, when discussing PDs obtained on-line, the 
following prison staff participant pointed out the risks involved, initially alluding to prisoners’ general 
indifference. However, the final sentence makes it clear that the circumstances around purchasing 
PDs from the internet is more complex, with greater risks to those more vulnerable, such as weaker 
prisoners being used to test substances on, before they are used by others. 
It’s a risky one 100%. As soon as you take something you have bought off the internet you are 
taking a risk anyway and a lot of these boys because it’s blue or yellow they assume it’s a blue 
or yellow and not necessarily so. So there is a lot of stuff coming in off the internet and it’s a 
lot stronger which is a problem. So a lot of it is being tested on other prisoners before they try 
it themselves - which is again, a form of bullying. (Prison staff, Prison B) 
To get a better understanding of motivation and what prompts people to make certain choices, it is 
important to look at how risks are perceived and subsequently managed and the basis upon which 
decisions are made or rejected. 
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SECTION FOUR – RISK AND RISK MANAGEMENT 
The concept of ‘risk’ is used here to frame our analysis. Interpretation of the data is aided by examining 
the way in which different perspectives of ‘risk’ and ultimately how that risk is managed, underpins 
decision making.   
Sociological theories are underlined by different understandings of risk, influenced by various 
academic disciplines (Zinn and McDonald, 2018). For example, some research that focuses on risk 
taking behaviour, attempt to understand what motivates people to make irrational choices that 
appear contrary to their best interests, such as smoking for instance. The concern here is to improve 
people’s judgement and encourage a move towards more rational decisions (Thaler and Sunstein, 
2009). However, very often solutions for improving risk behaviour fail because no account is taken of 
the context of people’s lives, how their environment affects behaviour and the ability people have to 
manage risk (Standing, 2011).  
Prisoners 
A nuanced theme that was present during interviews with prison staff was the suggestion that 
prisoners were either oblivious to the risks involved in the misuse of PDs – ‘people aren’t in here for 
having a great risk awareness’ or they were simply prepared to take a gamble. As one prison staff 
member (Prison B) explained: 
A lot of the stuff is coming in from America from the internet so they don’t actually know what 
it is. They just take a gamble on it and a lot of the stuff that comes from American is 5 or 10 
times the strength you get in the UK. 
Yet, discussions with all prisoners suggested there may be a higher risk awareness than prison staff 
presume. For example, prisoners were alert to the addictive nature of PDs, the higher risk of accidental 
overdose, the financial implications of dependence such as debt and bullying and the associated 
problems this posed for families on the outside and the consequences of detection (e.g. loss of 
privileges).  Some of the risks discussed by prisoners related to their own experiences of PDs (e.g. 
exacerbated mental health problems), other examples related to how PDs can lead to more dangerous 
drug taking addiction: 
From I’ve come in here, I’ve seen people move from prescription drugs to heroin, and it’s lethal. 
I’ve been here for three years and I’ve seen a big rise in people moving to heroin and I think 
the prescription drugs and opiates are a big part of that. (Prisoner, prison B)  
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When enquiring what the possible motives might be for their consumption, a number of key 
explanations emerged, one of which was self-medicating in response to having their regular 
prescribed medication reduced or removed.  
A common explanation given by prisoners was that changes to their medication while in prison 
prompted them to look for illicit medication to offset the effects of the change and/or to supplement 
what they were taking previously. 
We will take anything we can get because we can’t get what we are used to being prescribed. 
(Prisoner, Prison A) 
A number of prisoners drew comparisons between their previous medical treatment in the community 
with their treatment in jail, believing prison healthcare to be widely deficient. The vast majority of 
prisoners we spoke with had complex personal histories including childhood trauma, poor mental 
health; some had also been the subject of self-styled paramilitary assaults. Hence, almost all had a 
long-term profile of being on prescribed medication for various serious conditions. Over time, they 
had built up a high tolerance to the drugs they were being prescribed, requiring their medication to 
be increased to bring about the same impact. Therefore, their personal dosage was over and above 
what would be considered the normal standard dosage for anyone else. This is described below by a 
participant in Prison A: 
I remember my doctor saying to me, ‘you are technically overdosing every day, it’s just your 
body has built up a tolerance, whereas if you were to give somebody what you are being 
prescribed today they would die.  It just happens your tolerance is through the roof and you 
are needing to be prescribed more and more and more.’   
The same prisoner went on to explain why he believed moderating/stopping medication for someone 
like him, without proper detox management, encouraged people to seek illicit drugs and/or PDs 
diverted from other sources. The participant continued: 
The problem is, within the jails no one is getting detox, nobody is being brought down in an 
actual controlled environment, they are just stopping them and playing God with your life and 
then you have to go and get illegal drugs or prescription drugs or both depending on what you 
are being prescribed because you are trying to self-diagnose.   
There was a strong sense of grievance among prisoners at the prescribing practices within the prison 
environment. The general view was that the system operated along the line of suspicion, where all 
prisoners were being judged according to the actions of others. According to many prisoners, they 
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believed they were automatically presumed to be drug seeking if they approached the G.P. in prison 
with a medical complaint. Prisoners queried why their own G.P. felt it appropriate to prescribe certain 
medicines and yet prison healthcare staff felt it was reasonable to over-rule that decision. 
Deteriorating mental health status was a particular concern for prisoners, and was an area where it 
was felt the current prescribing regime was having a significant negative impact.  As one prisoner in 
Prison A phrased it: 
It’s important to highlight that 100% of men in this room have mental health issues and 
100% of the men in here are not getting the treatment in jail.  
Again, comparisons were drawn with life in the community. Prisoners felt that the prison authorities 
were attempting to address health issues in prison by employing similar methods as those used in the 
community. For example, the following participant had been receiving pain relief medication for seven 
years and had recently had his medication reduced. He described the doctor’s advice as ridiculous and 
said he would self-medicate if he got the chance because he did not believe his condition was being 
treated properly. 
I can’t get any prescription drugs to buy, but if I could buy them I would and treat myself 
normally because the doctors in here aren’t doing it.  There is one doctor down there…and he 
said ‘oh no you shouldn’t be still bad’ and I said arthritis gets progressively worse not better.  
Then he told me to lie in bed more… 23 hour lock up like! (Participant, Prison A) 
Pleasure seeking per se did not feature strongly as a motivational factor among prisoner discussions. 
Rather, explanations were couched in the ability of PDs to help ‘get the day in’ or to ‘take your mind 
off things’. Boredom and lack of alternative activities were among the reasons given by prisoners for 
considering that the consumption of PDs were worth the risk. Almost all prisoners noted that there 
should be extra activities, particularly for those prisoners who had their medication reduced or 
withdrawn. This is because prisoners felt that extra activities would act as a distraction from the effects 
of withdrawal and make up for the perceived lack of controlled detox facilities. Most of the comments 
referred to wanting additional gym sessions, expressly because their regular gym times had been 
reduced or terminated. Other comments referred to longer/additional sessions with AD:EPT. Services 
delivered by AD:DPT include advice on harm reduction and one-to-one counselling.  
The need for more structured education and training opportunities was another issue discussed, 
although not to the same extent. One participant (Prison A) expressed the desire for greater continuity 
between courses in prison and in the community, which would offer the possibility of following 
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through with higher level courses on the outside, as opposed to stopping once an intermediate level 
had been achieved.  This particular participant felt that the lack of opportunity to progress to the next 
skills level hindered the chance to gain a trade, delaying his options for rehabilitation: 
I am an NVQ level two joiner.  How am I being rehabilitated?  I can’t go and do level three.  I 
can’t even finish the rest of my trade.  I have to wait until I get out of here … wait and wait to 
go to tech to go back and do it. 
The legality of PDs was another key motivating factor. There was a sense that consumption of PDs 
involved less of a gamble because the consequences of getting caught with PDs were less than it would 
be for traditional illicit drugs. ‘Legality’ in this sense was also closely connected with issues of 
‘acceptability’ in that there was perceived to be less stigma surrounding PDs than illegal drugs. As one 
prisoner (Prison A) described it: 
It’s become more acceptable to be on medication than it is not to have any medication. 
The suggestion, from the follow-up quote made by another prisoner in the same focus group (Prison 
A) is that where acceptability leads, trends will follow: 
There seems to be more of a trend now, where people want prescription drugs, they don’t 
want illegal drugs now. 
The same participant went on to link the trend for PDs with issues of ‘quality’ (which emerged as a 
factor for increased availability), explaining how PDs are desired because the risk of getting a 
substandard (i.e. counterfeit) product is lower. He went on to explain further:  
They know what they are taking is going to be exactly what it says on the tin because it is hit 
or miss with illegal drugs.  You can get good cannabis, bad cannabis, good coke, bad coke, 
good heroin, bad heroin. (Prisoner, Prison A) 
It is not clear from the excerpt above if, by ‘getting exactly what it says on the tin’, the participant is 
insinuating that PDs reduce the risk of getting an inferior hit, or if desirability is driven by the 
perception that legitimate medicines reduce health risks, or both. What does emerge from the data 
so far is that motivation is inextricably linked to wider availability. 
Prison staff 
The increased non-medical use of PDs in prison also poses significant risks to prison staff and 
healthcare staff working in prisons, not only in terms of physical harm but also risks to their own 
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mental health and wellbeing. These risks also have to be managed during the carrying out of everyday 
duties. 
Just as prisoners talked about having their medication reduced or withdrawn, prison staff also 
discussed prescription practices and how this can sometimes place them in a very vulnerable position, 
particularly if a prisoner’s medication has been reduced or withdrawn without proper ‘step-down’ 
procedures. This was discussed in Prison A in much more depth than Prison B. Many Officers in Prison 
A reporting having to deal with the ‘fall-out’ from prescription practices and being left ‘to pick up the 
pieces’. Prisoners’ self-harming, conveying suicidal thoughts and causing general disruption after they 
have had their medication reviewed and/or reduced were some of the situations prison staff had 
experienced.  
Specific reference was made by a number of prison staff in prison A to the recent advice issued by the 
Health and Social Care Board (HSCB) specifically regarding the prescribing of pregabalin and 
gabapentin. The general guidance highlighted the risks of misuse and advised practitioners to 
prescribe pregabalin and gabapentin appropriately to minimise the risks of misuse and dependence 
(HSCB, 2015). Participants were of the opinion that the drugs were to be stopped and were concerned 
about the risks this posed about stopping the drugs without a back-up plan in place. As one participant 
noted: 
As of the new year, pregabalin in prison is being stopped and there’s no plan. It’s just if you 
take pregabalin, it’s being stopped. 
Another colleague in the same group added: 
I’m just curious as to what the plan for fallout is because there will be deaths from that. 
The general feeling here was one of frustration because Prison Officers believed they were being 
called on to deal with mental health issues, which was beyond their responsibility, and which they 
were not professionally trained to do.  
While the ‘fall-out’ from prescription medicine being removed included physical risks to their own 
safety, it also posed serious risks to their professional reputation and job security. This is because they 
believed incidents of self-harming, parasuicide and suicides are investigated on the basis of 
surveillance of Prison Officers’ actions as opposed to some of the other important factors such as 
prescribing practices for example: 
God forbid somebody did take their own life – the investigation will centre around us and what 
we have done and not the doctor and why the meds were stopped. (Prison staff, Prison A) 
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It was notable that prison staff picked up on similar issues raised by prisoners, albeit from their own 
individualised perspective. For example, the lack of alternatives available to prisoners who had their 
medication withdrawn was mentioned. Interestingly, additional sessions with AD:EPT and extra 
sessions in the gym were also proposed by prison staff as possibilities to help manage the issue: 
If we’re stopping people’s medications there should be something looked at to help them, 
whether it’s extra sessions with AD:EPT, whether it’s extra sessions in the gym – something 
else to focus their mind on apart from the medication. There’s no alternative being given – just 
your meds are stopped and that’s it. (Prison staff, Prison A) 
The recognition of AD:EPT as a positive initiative is noteworthy because the programme had not 
initially been well received by all Prison Officers. As the following participant explained, the 
programme content (e.g. awareness raising, harm reduction) had raised some suspicion among his 
colleagues, but this had waned as the programme developed: 
…we were extremely annoyed about it but in hindsight it was the right thing. They gave them 
pieces of paper saying ‘if you have got it, this is how you cut it up and use if safely’. Harm 
reduction…in hindsight now it probably was the right thing to do to save lives. (Prison Officer, 
Prison B) 
Similarly, the discord between styles of healthcare provided in the community and healthcare 
provided in prison also featured in discussions with prison staff. Staff we interviewed talked about the 
disconnect between trying to address health issues in the prison environment in a similar way to how 
it is tackled in the community. This echoes the views of prisoners who queried the relevance of advice 
offered by healthcare staff. The Prison Officer explained it this way: 
When prisoners come in here they’re guaranteed the same level of healthcare as they have on 
the outside, that doesn’t follow through...There are leaflets they give out about stress and 
anxiety, take a long walk… you know they can’t take a long walk in here. Get a good night 
sleep – there are certain things like, we have to wake them at 7am for a response check, make 
sure they’re still alive, but this is still the literature they give out. On the outside, the person 
who gets their medication stopped can go for a long walk, can go and speak to a free 
community counsellor, these are not things that can happen on the inside. 
When discussing widening use of PDs, prison staff gave examples of certain clandestine behaviour that 
they believe some prisoners engage in to obtain PDs – both inside and outside of the prison 
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establishment. Examples ranged from extreme action like arranging their own shooting, as the 
following prison staff participant explained: 
The prisoners will tell you, some have organized their own shooting to get all that 
medication, to get DLA. Just because they’re not risk aware, doesn’t mean they’re not 
cunning. Straight away you get DLA if you’re prescribed pregabalin. (Prison staff, Prison A) 
In this case, financial gain is deemed to be an additional motivating factor as particular PDs are 
believed to open doors to receipt of disability benefit.  
Other examples given by prison staff included prisoners deliberately self-harming to get PDs: 
There are people in here who would actually throw the challenge out to you and they’ll go to 
the nurse and if she says ‘you’re not getting that’, they’ll say ‘oh, am I not?’ – and the door 
closes and the rope goes up. Probably an hour or two later they will have got what they 
wanted…and they’ll say ‘I told you so’. (Prison Officer, Prison A) 
Less extreme examples included prisoners presenting to their G.P. in the community before they come 
into prison to ensure that specific PDs are recorded in their medical notes. They also described 
incidents of prisoners presenting to the prison G.P. with exaggerated symptoms to try to get their 
medication increased, either for self-use, or diversion, or as a result of bullying by other prisoners.  
However, the biggest risk was considered to come from PDs being brought into prison at specific 
points.  
Common pressure points across both prisons were identified as PDs being smuggled in during visits, 
prisoners coming back from home leave, returning from work outside of prison or from prisoners who 
have been released and have ended up returning to jail soon afterwards.   
Physical risks to prison staff were associated with low staffing levels by participants in both prisons.   
Participants in Prison B highlighted discrepancies between staffing levels during the day compared to 
night time as potential vulnerable risk points, believing more manpower would reduce the use of PDs 
in prison. Prisoners suspected of being at risk of overdosing on PDs are given their medication via 
supervised swallow. While this was thought to alleviate risks as a consequence of overdosing, at the 
same time the additional work that supervised medication requires was thought to generate another 
pressure point. This is because supervising prisoners’ medication in general already takes up so much 
time:  
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The whole meds list for the morning, between mental health and all the rest was 135 prisoners, 
that was between 2-3 staff between the hours of 9am and mid-day, which by anyone’s 
standards, you’re a miracle worker if you can facilitate that. (Prison Officer, Prison A) 
Lack of engagement between prison staff and healthcare staff emerged as another point of 
contention. This was mostly discussed in the context of conflict between prison staff being kept 
uninformed about a prisoner’s medical profile and healthcare staff defending patient confidentiality. 
Discussion centred around the view that prior knowledge would help prison staff manage risk more 
easily. Some of the risks were associated with potential physical harm to staff emanating from 
infectious conditions versus prisoners’ human right to privacy: 
…because of their human rights and because of article two rights5, we’re not allowed to know. 
My article two [rights] apparently doesn’t matter. (Prison Officer, Prison B) 
Some Officers alluded to power struggles between medical staff and mental health teams, feeling that 
this left Prison Officers even more powerless as they felt they could not get involved in medical 
disputes. Generally, it was thought there should be clearer protocol regarding lines of engagement 
among all staff. 
However, the issue of being kept informed provoked some ambivalence, as other Prison Officers felt 
that not being privy to medical information actually helped them manage risk better. This was because 
distance from medical information shifted the onus of accountability for mental and physical health 
issues back to the medical profession. This is how one Prison Officer in Prison A explained it: 
They come to us bumming and blowing and crowing and roaring ‘I’ve been taken off my 
meds’. My go to line is ‘that’s an issue between you and the Trust – I’m a prison officer – 
that’s a medical issue’. 
Connected to being kept informed was the perceived gap in knowledge between prison staff and 
prisoners regarding what participants referred to as ‘jail pharmacology’. Participants recounted 
previous training on drugs awareness that they received which was regarded as totally inadequate 
and antiquated. At least one prison staff member talked about looking up google to get information 
on why certain PDs were being requested. Others said they got their information from prisoners. This 
lack of knowledge was thought to potentially increase risk (to themselves and prisoners) because they 
                                                          
5 This refers to Article 2 of the Human Rights Act 1998: Right to Life. The Human Rights Act sets out the 
fundamental rights and freedoms that everyone in the UK is entitled to. See 
https://www.equalityhumanrights.com/en/human-rights/human-rights-act 
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did not fully understand the symptoms of certain drug combinations, hence they were unprepared for 
the consequences. 
Healthcare staff 
Like prisoners and prison officers, healthcare staff also connected the issue of PDs with what is 
happening in the community. Links were also drawn with the legacy of the Troubles, as was a lack of 
alternative community services. However, healthcare staff were more likely than other participants to 
move beyond these issues by also locating the issue within the context of prisoners’ traumatic life 
experiences and socio-economic circumstances like deprivation and poverty. All of these issues are 
combined in the one quote below: 
I don’t think they are using them anymore in here than they are using them on the outside, so 
people always think that prison is worse but it’s not. If you went into West Belfast, into one of 
the apartments up there you know you would see it or North Belfast, East Belfast, anywhere 
you know? Some of the more deprived areas. Why do they use it? Probably easy access to be 
honest. Northern Ireland historically has been an over-prescriber of medication as you know, 
whether that’s historically form the troubles, from all the traumas or actually to be honest a 
lot of it is from a lack of funding to alternative services in the community. So what else is there 
to deal with this young fella whose dad was blown up, you know? They can go the WAVE in 
North Belfast but once that runs out where do they go? And then that’s when they end up 
getting on lots of tablets, so that is a big issue. (Healthcare staff, Prison A) 
For those providing healthcare, the desire to respond to patient need is innate, but this is constantly 
challenged by the need to be more circumspect about prescribing for patients in prison than those 
outside prison. The inherent health risks associated with the concurrent use of multiple substances 
within a pattern of polydrug use was noted by healthcare staff as significant.  
Responsibility for managing risk is set out in guidelines issued by the Royal College of General 
Practitioners (RCGP) for clinicians on safer prescribing practices within the prison environment. 
Healthcare staff have to balance individual patients’ health needs against security and safety risks. But 
not only do clinicians have responsibility to the patient, they also have a duty to reduce risk to the 
prison population (RCGP, 2011). 
Healthcare staff we spoke with recognised themselves as a means of access to PDs, open to patients 
presenting with exaggerated symptoms to obtain specific drugs which could result in personal misuse 
or the PDs being diverted to others – either by selling on or through bullying (which aligns with what 
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prison staff said). When asked if such risks impacted on prescribing practices, the following participant 
agreed that they did: 
Definitely, we have different guidelines so there is really quite tight guidelines for prescribing 
in prison so the World College of Psychiatry have a joint documents called Safer Prescribing in 
Prisons, NHS have a pain prescribing in prisons formula that we use so it’s actually very 
different to the community so we are a lot less likely to give pregabalin in here, it just won’t 
happen. (Healthcare staff, Prison A) 
However, the guidelines alluded to in the above quote also state that ‘The standard of care should be 
equivalent to the standard that is delivered in the community’ (RCGP, 2011: 7). Yet, as emerged in 
discussions with prisoners and prison officers, treatment in the community and treatment in prison 
can be at odds with each other, given the greater level of responsibility and, ultimately accountability, 
placed on the healthcare professional. This was succinctly explained by a clinician in Prison A, who 
pointed out the lack of liability for choices made by patients in prison and how that liability is 
transferred to health professionals: 
With us, our main issue is looking after them so as a GP in [town] I have to look after somebody 
sure, but whenever they are in their own house they have to take certain responsibility for their 
own actions. Whereas here, we look after them 24 hours a day so that’s why we are tighter. If 
anything happens to our patients here - the buck does stop with us. 
The safe administration of medication emerged here (as it did with prison officers) as a pressure point 
in terms of demand on resources. Although in this case, it was discussed more in relation to time and 
financial pressures as opposed to physical risk. Healthcare workers were obliged to carry out ‘risk 
assessments’ with new prisoners to ascertain if they could safely be in possession of PDs. Medication 
will be reviewed if it is deemed excessive and reduced accordingly. According to the majority of 
participants, the number of people requiring supervised swallow was increasing exponentially.  As a 
result, any additional resources were being averted for risk avoidance and surveillance purposes, 
when they could be used for other more beneficial purposes. Diversionary activities featured again, 
such as gym classes, cookery and self-development courses:  
I think more gym, that’s what we are trying to push for now. It’s just the resources we have. 
We would want to be doing cookery classes, all the self-esteem, all these different groups that 
are going to benefit them and their recovery and make them feel better about themselves.  
(Healthcare staff, Prison B) 
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Pressure points 
The pressure points discussed previously were identified by healthcare staff as a type of ‘revolving 
door’, more prevalent at stages of entering, leaving and returning to prison.  Examples given echoed 
those expressed by prison officers:  offenders going to their G.P. in the community prior to entering 
prison to ensure they have specific drugs on their medical record in a pre-planned strategy  to increase 
their chances of obtaining prescription medication in prison; attempting to have their medication 
upped by the prison G.P. prior to release, in order to ‘stockpile’ before going back into the community; 
smuggling PDs when re-entering prison, either for self-use, or to use as a form of currency, or as a 
result of being bullied into it by other inmates. 
Connected to these pressure points was the risks attached with potential for slippage in terms of 
continuity of a patient’s treatment between prison and the community. A case in point was a patient 
who had left prison one day, went to see his G.P. the next day, and was prescribed pregabalin, which 
the prison G.P. had earlier decided was not in the best interests of the patient. The same patient 
returned to prison a month later, with pregabalin recorded in his medical records. This underscores 
the difficulties involved in trying to harmonise healthcare between prison and the community. 
Developing and maintaining good links with community teams was emphasised as essential for 
minimising such potential risks.  
Paradoxically, it was the opinion of at least one clinician that the chances for improvement were better 
if the person was serving a longer sentence. In these circumstances, there was time to put a proper 
recovery plan into action, as opposed to those in prison for short periods of time who were merely 
being ‘looked after’ temporarily and getting caught up in the ‘recycling process’ described above: 
The short-term remand and fines and things, you can’t do anything with those guys, you have 
got to keep them safe, try to reduce the risk of them taking an overdose while they are here 
and making sure they don’t do themselves any major harm in the few months…if they’re not 
here for a long period of time, it’s very difficult. At the end of the day we are only looking after 
them on a temporary basis, they are all registered with G.P.s in the community so the burden 
and responsibility as a G.P. in the community lies in the community and the vast majority of 
our patients, 95% of them will come in and out of here reasonably quickly…  
(Healthcare staff, Prison A) 
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Related to this, another suggestion proposed for easing the pressure points caused by this ‘revolving 
door’ process was the introduction of Drug Courts6:  
… if there was a drug court type thing, because people come in here and they are actively on 
the abusive substances and that’s why they have committed a crime so trying to actually get 
to the bottom of that and say how within crime can we get rid of this to try and stop you, time 
in prison for that is not going to help you that much. (Healthcare staff, Prison A) 
As noted earlier, healthcare staff in both prisons were more likely than other participants to raise the 
issue of personal trauma in connection to the misuse of PDs, highlighting the extent to which traumatic 
experiences impacted negatively on the mental health of patients they treated. While some prisoners 
talked about violent traumatic incidents connected with paramilitary activity such as punishment 
beatings, shootings and so forth, they were less forthcoming about trauma of a personal nature. This 
is most likely due to the methodology and the fact that discussions were conducted via focus groups.  
Almost all healthcare participants expressed the desire for a more holistic style approach to managing 
risk in prison.  Participants in Prison A and B also expressed their frustration at what them deemed a 
‘vicious circle’ where often mental health problems are not given priority for treatment until the 
patient’s drug problem has been tackled. However, participants pointed out that the drug problem 
cannot be tackled until the mental health issues have been addressed.  
What emerged in these discussions was an appreciation of the benefits of a whole person approach 
to treating substance misuse, which included the need for a better understanding of addiction. 
Greater education on addiction, mental health issues and a move towards trauma informed practices 
in the prison environment and in the community were suggested as priority areas, if the issue of PDs 
is to be successfully addressed: 
It definitely is…there was a paper published in the last couple of weeks…in relation to moving 
away from that punishment and moving towards the trauma informed practice and how we 
look at that person. It’s done in other countries; could we replicate this? It’s probably 
something we should be looking at. (Healthcare staff, Prison A) 
                                                          
6 Drug Courts are a component of Problem Solving Courts and have been introduced in many countries as a 
way of reducing drug-related imprisonment by offering court supervised treatment for drug dependence 
(UNODC, 2007).  The initiative works with people whose offending behaviour is driven by alcohol or drugs 
misuse. International evidence suggests that this type of intensive treatment is a more effective intervention 
to rehabilitate offenders (CJI, 2015). 
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The reference here to ‘trauma informed practice’ is an indication of the increasing recognition of the 
detrimental impact of multiple adversities in childhood on health and wellbeing outcomes in later life 
(e.g. Bellis et al., 2015; Felitti et al., 2010; Hughes et al. 2017 – cited in Mooney and Coulter 2019). The 
term ‘trauma informed care’ is now a common approach used in health and social care, particularly 
among early years’ practitioners.  This has led to recommendations for the UK Government to draw 
up a new national strategy for ‘evidence-based early intervention aimed at addressing childhood 
adversity and trauma’ (HoC, 2018: 4).  
As noted above, health professionals have become more aware of the mental health needs of 
individuals and families impacted by trauma (and transgenerational trauma) as a legacy of the 
Troubles – many of which use alcohol and other drugs, ‘leading to high rates of comorbid mental and 
substance use disorders’ (Commission for Victims and Survivors, 2015: 10). 
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SECTION FIVE – SUMMARY AND RECOMMENDATIONS  
Analysis of the data revealed a number of main points. These are summarised below: 
It is the perception of those who took part in this study that prescription drug use is a major issue in 
Northern Ireland and has increased substantially over the past three to four years. The belief is that 
PDs now surpass illicit drugs in terms of supply and demand. Where once NPS were in high demand, 
the trend has moved to one of PDs within an overall polydrug use, which carries a higher risk of 
overdosing and adverse consequences (HMIP, 2015).  
Throughout this study, a prominent message which emerged was that the use of PDs is a reflection of 
society as a whole. In other words, it is not a ‘prison problem’, rather a challenge that confronts society 
in general. This brought into sharp focus the relevance of overlaying some of the more common 
community based advice such as going for a long walk and getting plenty of rest, onto the prison 
population, where such suggestions are not realistic.  
Comparisons were drawn between the increased use of PDs in prison with historic patterns of 
prescription practices in Northern Ireland overall, particularly of sedatives in the treatment of anxiety 
and depression. Many participants linked high and increasing levels of PDs for mental disorders to 
high rates of mental health problems in Northern Ireland associated with socio-economic deprivation 
and the legacy of the political conflict. 
Factors which repeatedly featured in discussions with all participants about the drivers of increased 
availability of (and demand for) PDs centred on cost, profit, evasion, suppression and quality. PDs are 
cheaper than traditional illicit drugs, with the emergence of the ‘dark web’ making them easy to 
obtain. PDs are easier to conceal and harder to detect as sniffer dogs are only trained to detect mostly 
illicit substances. Certain prescription medication is also quicker to leave the body, meaning there is 
less chance of being detected in a drug test. The legality of PDs was thought to offset potential 
consequences of being in possession, compared to more traditional illicit drugs. Greater availability of 
PDs makes access easier, fuels demand and is inextricably linked with motivational factors. All of these 
factors are reported in the wider literature. 
The extent to which prescribing practices in prison was referred to during this study is an indication of 
how significant the issue is to all participants alike.  For example, when motivations for using PDs was 
discussed with prisoners, the conversation more often centred around the use of PDs as a response 
to their prescribed medication being moderated/terminated while in jail. This was noticeably more 
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dominant among prisoners in Prison A than it was in Prison B. The notion of ‘self-medicating’ was a 
significant sub-theme here.  
While ‘self-medicating’ did feature to an extent in Prison B, it was more prevalent in Prison A. This 
may be due to the fact that, as detailed in Table 1, participants in Prison A were part of an established 
group which met weekly to discuss issues related to substance use and their general day to day 
wellbeing. Thus, making health and wellbeing matters a prominent focus.  
It was the view of some prison and healthcare staff that wide availability is also driven by prisoners’ 
deliberate actions, both inside and outside of prison, to increase the likelihood of being prescribed 
certain drugs legitimately. Actions included self-harming, presenting to their community G.P. and/or 
prison G.P./Psychiatrist with untruthful or exaggerated conditions. This was believed to be for multiple 
overlapping reasons such as financial gain, for example as a door to disability benefits, to use as 
currency on the black market, for diversion purposes, as a result of bullying and so forth. All of which 
brings into question the medical grounds underpinned in prisoners’ explanations for self-medicating.  
Pleasure seeking per se did not feature strongly as a motivational factor among prisoner discussions. 
Rather, explanations were couched in the ability of PDs to help ‘get the day in’ or to ‘take your mind 
off things’. Boredom and lack of alternative activities were among the reasons put forward for the use 
of PDs. 
The biggest issue in terms of accessibility to PDs was thought to be medication being brought into 
prison from outside. Common pressure points for bringing PDs into prison was identified as during 
visits, prisoners coming back from home leave, prisoners returning from work outside of prison and 
from those who had been released and had gone on to reoffend.  
The perceived safety of PDs compared to illicit drugs was a topic that emerged among all participants. 
Prison and healthcare staff tended to have the opinion that prisoners had less risk awareness about 
the adverse consequences associated with counterfeit PDs. However, discussions with prisoners 
revealed that was not necessarily the case, with awareness of risk being weighed against the 
consequences.  
Reduced staffing levels were discussed by prison staff as adding to the risks involved in PD use, closely 
connected to this was the time pressures involved in the safe supervision of medication and the belief 
that medication queues offered the potential for bullying.  
Among the grievances expressed by prisoners was the perceived differential medical treatment 
between what they received in the community from their own G.P. and the treatment received in the 
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prison environment. At the same time, health care staff had to guard against the misuse of PDs 
through dishonest or exaggerated demands for treatment. Health care staff are also bound by 
restrictions placed on medical staff about prescribing practices in prison. 
One issue which was reiterated on several occasions by all participants in the study was the matter of 
diversionary activities, of which increased exercise time and access to the gym were prominent, but 
also included cookery classes and self-development classes. The general opinion was that diversionary 
activities, particularly physical exercise, occupied the mind and was a positive thing. 
Discussions with healthcare staff emphasised the need for greater education on addiction and the 
value of a holistic approach to addressing this issue, that is, understanding what benefits the person 
as a whole, including their mental, physical and emotional health – not just for those working in the 
prison estate but right across the community.  
Reflecting on the findings, one of the most important points to emerge is that addressing the issue of 
PDs in prison cannot be undertaken in isolation. It is difficult to contemplate any resolution that does 
not simultaneously take into consideration the use of PDs in the wider community. 
This suggests that strategies designed to encourage a community-wide holistic approach that 
minimises risk involved in PDs as they sit within the wider polydrug use may be more successful than 
other initiatives that try to deal with the situation separately. A dedicated communications network 
between professionals working in the prison environment and those working in the community that 
prioritised sharing of information and experiences - on emerging trends for instance -  would be one 
such example. 
Health care staff expressed the opinion that patients in prison do not take enough responsibility for 
the choices they make, consequently that responsibility is passed onto health professionals. This not 
only increases accountability on behalf of health staff, but frees patients from fully contemplating the 
consequences of their actions. This ties in with recent moves in Northern Ireland to introduce 
initiatives that would see prisoners being encouraged to take more responsibility for their actions 
through behaviour change approaches.  
The meaning applied to ‘risk’ in the study was associated with consequence and weighing up the pros 
and cons of following up a line of action. This pointed to motivational factors that reflect those 
documented in other reports examining the issue of substance misuse in prisons such as increased 
availability driven by cost, profit, concealment and evasion factors (e.g. CJINI, 2018; 2016; CSJ, 2015; 
HMIP, 2015). Therefore, many of the recommendations made in these reports will also be relevant to 
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this study. However, there are some aspects of Northern Ireland society that require a slightly more 
nuanced approach; a better understanding of trauma (including transgenerational trauma) and its 
impact on drug taking behaviour is a case in point. 
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Recommendations 
 Given the strength of the finding that the pattern of PDs practice in prison is a reflection of 
the wider community, it would be good practice to develop and maintain solid communication 
links with organisations in the community for the sharing of information on emerging local 
trends. This would allow the characteristics and traits of new and emerging drugs to be 
recognised more quickly and planning put in place for how to deal with the issue. 
 In addition to other services, AD:EPT offer a pre-release session aimed at those due for 
release, looking at how to reduce risk when released from custody. Information and advice is 
provided on drugs and alcohol use and AD:EPT work with the client to prepare plans for 
reintegration in the community. This is a good opportunity to address the delineation that 
participants believe exists between treatment in prison and the community. However, future 
funding of the programme is uncertain and we believe the service should be adequately 
funded to maintain this work.   
 Many prisoners expressed the desire for access to substance misuse treatment and prison 
staff also pointed to the lack of such facilities. On the basis of what participants told us, there 
should be consistent access to controlled detox facilities/mechanisms for ‘step down’ in place 
within prisons in Northern Ireland. 
 All prison staff should be alert to potential situations where more vulnerable prisoners may 
be used to ‘test out’ substances by others, prior to their use.  
 All participants thought diversionary activities, particularly physical activity, were positive 
ways of distracting attention from the effects of withdrawal and making up for the lack of 
controlled detox facilities. Cookery classes, personal development classes and, in particular, 
gym sessions provided on a routine basis, rather than as a privilege would be an opportunity 
to test this notion. 
 Prison and healthcare staff noted an information gap between themselves and prisoners in 
‘jail pharmacology’. Resourced and up-to-date training should be available for all prison staff 
who request it, to understand the symptoms and consequences of prescription and other drug 
use and how to deal with it.  
 Efforts should be made to develop an integrated trauma Informed practice model in prison, 
drawing on examples that have advanced in the social care field.  
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